Eli Lilly, Boehringer Ingelheim’s Jardiance Giving Competition to AstraZeneca’s Farxiga with EU Approval
Jardiance, the diabetes blockbuster from Eli Lilly and Boehringer Ingelheim, recently received a Heart Failure label expansion in the United States. Now, the drug is expanding into Europe, with a nod that might help it catch up to it’s rival i.e. AstraZeneca's SGLT2 Farxiga.
The EU made its decision based on the findings of Jardiance's late-stage EMPEROR-Preserved study, which revealed that the medicine reduced the risk of cardiovascular death or heart failure hospitalization by 21%. According to Boehringer, the drug's benefit was found regardless of the pati...
